
    
      The purpose of this study was to provide efficacy and safety data on 0.5 mg ranibizumab
      intravitreal injections compared to laser photocoagulation in Chinese patients with visual
      impairment due to DME. Treatment was driven by achieving vision stabilization.
    
  